Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
  • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
  • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
  • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates to a long-acting sustained release preparation of a dopamine receptor agonist drug, and more particularly, the present invention relates to a sustained release microsphere for injection of a dopamine drug, an implant and an injection gel, and a preparation method thereof, and the use thereof
• Method for preparing a compound for treating or adjunctively treating a disease associated with a dopamine receptor and for treating a long-acting sustained-release preparation for a Parkinson's disease such as Parkinson's disease or Parkinson's disease (hereinafter referred to as Parkinson's disease) It is the method of microspheres.
• Background technique is the method of microspheres.
• Dopamine agonists are an important class of drugs for the treatment of Parkinson's disease.
• the current dopamine agonists used in the clinic are doxyamine agonists.
• the above drugs are often administered clinically in oral or transdermal formulations.
• oral administration is convenient, patients with advanced Parkinson's disease are often accompanied by memory loss, which may lead to the deterioration of the disease; in addition, the concentration fluctuates greatly after oral administration, which leads to an increase in side effects and a "switching effect";
• the first pass effect of the liver and liver leads to a decrease in bioavailability.
• roticotine has a low oral bioavailability of only 1% to 5% due to the first pass effect of the liver, so it is not suitable for oral dosage forms.
• there are insufficient transdermal absorption of ordinary transdermal preparations such as ointments and plasters, and there are many factors affecting transdermal absorption.
• the changes are often changed, and the transdermal absorbent is affected by the low permeability of the skin, which also results in low intake, low bioavailability, and large individual differences.
• the therapeutic effect is limited, especially for patients with advanced Parkinson's disease.
• the efficacy is very limited.
• Parenteral administration such as administration, can avoid first-pass effects, but since roticotine and pramipexole have short half-lives, only a few hours, multiple doses per day are required.
• Other drugs although relatively long-lived, require at least one or the other day, and therefore are not conducive to administration to patients with Parkinson's disease.
• a long-acting sustained-release preparation of a scale dopamine receptor agonist drug preferably without oral administration, but for example, by intramuscular or subcutaneous administration, while continuously and smoothly releasing the drug for several weeks, several Months are even longer to minimize the pain of taking medicine for patients with Parkinson's disease.
• CN1531428A discloses a Depot form sustained release preparation of roticotine in which a so-called “reservoir” obtained by suspending roticotine hydrochloride in an oily solvent is used, The dosing interval was extended to more than one day.
• the sustained-release preparation can stably release the drug in the body for a long period of time, so that the patient can remain effective during the above-mentioned administration period.
• the blood concentration, but also the injection of the drug into the body does not produce excessive side effects.
• the preparation of the sustained release preparation not only requires strict requirements on the scope of use of the drug amount, but also the use of the auxiliary material and the range of its use are also required to be strict. Only in this way can we truly take the medicine once a week or more, or even a month, and achieve a good therapeutic effect.
• the present inventors have conducted intensive studies for the purpose of realizing long-release and slow-release of dopamine receptor agonist drugs, and found that sustained release microspheres and implants for injection are prepared by uniformly embedding drugs with biodegradable polymers. And injection gels, etc., through muscle or subcutaneous administration, can continuously release the drug for several weeks to several months, and have the advantages of high bioavailability, small fluctuation of blood drug concentration, and greatly reduced number of administrations. Compared with traditional oral preparations, it can reduce the occurrence of side effects, reduce the frequency of "switching effect", and significantly improve bioavailability, increase patient compliance, and maximize the therapeutic effect of such drugs.
• the present invention has been achieved based on the above findings. Disclosure of invention
• An object of the present invention is to provide a long-acting sustained-release preparation of a dopamine receptor agonist drug, specifically, for example, an injection microsphere, an injection gel, and an implant.
• the invention can reduce the frequency of drug use from one or more times a day to one week, two weeks, one month or even two months and even longer time, greatly reducing the number of medications, avoiding the first pass effect and improving the bioavailability of the drug. And the therapeutic effect, which greatly reduces the suffering of patients with Parkinson's disease and improves their quality of life.
• the above object of the present invention can be achieved by the technical solutions described below.
• the present invention provides a long-acting sustained-release preparation of a dopamine receptor agonist drug, particularly roticotine, such as an injection microsphere, an injection gel, an implant or the like, particularly a microsphere for injection.
• the present invention further provides a method of treating a Parkinson's disease patient with a long-acting sustained release preparation of a dopamine receptor agonist.
• the present invention relates to:
• a long-acting sustained-release preparation for treating Parkinson's disease comprising an effective dose of a dopamine receptor agonist drug and a biodegradable medicinal polymer adjuvant, wherein the dopamine is subjected to
• the weight of the body drug in the sustained release preparation is 5 - 50%, and the weight of the pharmaceutical polymer adjuvant in the sustained release preparation is 50 - 95%.
• Dopamine receptor agonists are roticotin, pramipexole, ropinirole, pergolide, cabergoline, terguride, quetiapine, sumanirole, SLV-308, adrogol ide (ABT-431) ), one or a combination of two or more of Dinapsol ine and BAM-1110 and their derivatives or pharmaceutically acceptable salts.
• the biodegradable medicinal polymer auxiliary is selected from the group consisting of polylactide, polylactic acid, polyglycolic acid, poly-3-hydroxybutyrate, polylactone, polyanhydride, polyhydroxybutyrate hydroxyvalerate copolymer One, two or more combinations of the materials, polypropylene dextran, polylactic acid-polyethylene glycol, and polyglycolic acid-polyethylene glycol.
• the long-acting sustained release preparation of the above dopamine receptor agonist is preferably an injection microsphere, an injection gel, an implant or the like.
• the above dopamine receptor drug is preferably present in the form of a solid solution in the sustained release preparation.
• the biodegradable medicinal polymer material is preferably selected from the group consisting of polylactide-glycolide, polylactic acid, polycaprolactone, polyanhydride, and polyhydroxybutyrate-hydroxyvalerate.
• polylactide-glycolide polylactic acid, polycaprolactone, polyanhydride, and polyhydroxybutyrate-hydroxyvalerate.
• One, two or more combinations of the copolymers More preferably, one, two or more of polylactide-glycolide, polylactic acid and polyanhydride are combined.
• Particularly preferred is polylactide-glycolide, especially polylactide-glycolide having a molecular weight of from 5,000 to 100,000 Daltons.
• the polymerization ratio of lactide and glycolide is 95:5 - 5:95, preferably 75:25 - 25:75.
• the pharmaceutically acceptable salt thereof is a salt formed from a pharmaceutical ingredient and an inorganic acid, an organic acid or an acidic amino acid.
• the inorganic acid is hydrochloric acid, sulfuric acid, phosphoric acid or nitric acid
• the organic acid is citric acid, fumaric acid, maleic acid, acetic acid, benzoic acid, sulfonic acid, naphthalenesulfonic acid or p-benzoquinonesulfonic acid
• Amino acid or aspartic acid is hydrochloric acid, sulfuric acid, phosphoric acid or nitric acid
• the organic acid is citric acid, fumaric acid, maleic acid, acetic acid, benzoic acid, sulfonic acid, naphthalenesulfonic acid or p-benzoquinonesulfonic acid
• Amino acid or aspartic acid is hydrochloric acid, sulfuric acid, phosphoric acid or nitric acid
• the organic acid is citric acid, fumaric acid, maleic acid, acetic acid, benzoic acid, sulfonic acid, naphthalenesulfonic
• pramipexole and its derivatives or pharmaceutically acceptable salts are the free base of pramipexole or the dihydrochloride of pramipexole; etc.; ropinirole and its derivatives or pharmaceutically acceptable salts are ropinirole
• the free base or the hydrochloride salt of ropinirole; the pergolide and its derivatives or pharmaceutically acceptable salts are the free base of pergolide or the mesylate salt of pergolide; cabergoline and its derivatives Or the pharmaceutically acceptable salt is the free base of cabergoline or the bisphosphonate of cabergoline;
• the terguride and its derivatives or pharmaceutically acceptable salts are the free base of terguride or the maleate of terguride;
• the quetiapine and its derivatives or pharmaceutically acceptable salts thereof are the free base of quetiapine or the hydrochloride salt of quetiapine; the sumanirole and its derivatives or pharmaceutically acceptable salts
• SLV-308 and its derivatives or salts are SLV-308 free base or SLV-308 hydrochloride
• adrogolide C ABT-431) and its derivatives or pharmaceutically acceptable salts are adrogolide, adrogolide hydrochloride Or its transformant A - 86929; Dinapsoline and its derivatives or medicinal for dinapsoline or dinapsoline Hydrobromide and the like
• BAM- 1110 or its pharmaceutically acceptable salt is a biological imperative BAM- 1110 or BAM-1110 maleate and the like.
• roticotine and its derivatives or pharmaceutically acceptable salts represented by the following formula (la) are most preferred:
• An alkanoyl or an aromatic acyl group (preferably a hydrogen atom, a C 2 -C 4 alkanoyl group or an aromatic acyl group);
• R 2 represents a hydrogen atom, a d-C 1 () alkyl group; preferably a C 2 -C alkyl group;
• X represents a carbon atom or a nitrogen atom or an oxygen oxime or a sulfur atom;
• n is any one of 1-10 (preferably 1-3);
• the pharmaceutically acceptable salt thereof is roticotine free base and hydrochloric acid, acetate, phosphoric acid, sulfuric acid, lactic acid Or a salt of citric acid.
• Rotibutines preferably roticotine ethyl ester, roticotine methyl ester, rotibuteryl propyl ester, roticotine butyl acrylate and roticotine isobutyl ester and its hydrochloride.
• the dopamine receptor agonist drug has a weight content of 10 - 40%, and the medicinal polymer adjuvant has a weight content of 60 - 90%; the optimal escaped dopamine receptor agonist drug and the drug
• the weight ratio of the polymeric excipients is (10 - 30): (90 - 70).
• the particle diameter thereof is preferably between 470 and 200 ⁇ m.
• Figure 1 is a graphical representation of the differential thermal analysis of rotibutine microspheres at various levels.
• Fig. 2 is a graph showing the particle size distribution of the sustained release microspheres obtained in Example 1.
• Fig. 3 is a scanning electron micrograph of the sustained release microsphere obtained in Example 1.
• Fig. 4 is a line diagram showing the per enthalpy and cumulative release rate of the sustained release microspheres obtained in Example 1 in a simulated release liquid of H7.4.
• the mouth indicates the daily release amount, and the cumulative release amount.
• Fig. 5 is a line graph showing the per enthalpy and cumulative release rate of the sustained-release microspheres obtained in Example 2 in a simulated release liquid of pH 7.4.
• ⁇ indicates the daily release amount
• * indicates the cumulative dry release amount.
• Fig. 6 is a line graph showing the growth rate and cumulative release rate of the slow microspheres obtained in Example 3 in the simulated release night of H7.
• ⁇ indicates the amount of daily dance
• • indicates the cumulative release amount.
• Figure 7 is a line graph of the daily release of the sustained release microspheres obtained in Example 4 at pH 7.4, and the cumulative dry release rate.
• ⁇ indicates daily dry release
• • indicates cumulative release.
• Figure 8 is a line graph of the enthalpy and cumulative dry rate of the sustained release microspheres obtained in Example 5 in a simulated release solution of pH 7.4.
• the mouth indicates the daily dry release
• * indicates the cumulative dry release.
• Figure 9 is a line graph of the cumulative release rate of the sustained release microspheres obtained in Example 6 in a simulated release solution at pH 7.4.
• ⁇ indicates the daily axe volume
• the climb indicates the cumulative release.
• Figure 10 is a line graph showing the daily and cumulative release rates of the slow-drying microspheres obtained in Example 11 in a simulated dry drain of pH 7.4.
• ⁇ indicates the daily release amount
• * indicates the cumulative release amount.
• Figure 11 is a line graph of the cumulative release rate of the sustained release microspheres obtained in Example 13 in a simulated dry discharge solution at pH 7.4.
• the mouth indicates the daily release
• the climb indicates the cumulative release.
• Fig. 12 is a graph showing the change in concentration of rotibutine in the blood of the sustained-release microspheres obtained in Example 3 in an in vivo experiment (Beagle).
• Figure 13 is a line graph of the daily or cumulative release rate of the slow-drying microspheres obtained in Example 3 in the simulated release solution of H7.4, and a line graph of the concentration of rotibutine in the blood of the in vivo experiment (Beagle). Comparison.
• the mouth indicates the blood concentration, and the reference indicates the daily release.
• Figure 14 is a line graph of the daily in vitro and cumulative release rate of the implant obtained in Example 20.
• the mouth indicates the daily release amount, and ⁇ indicates the cumulative dry release amount.
• Fig. 15 is a line graph showing the daily in vitro and cumulative release rate of the gel for injection obtained in Example 22.
• the mouth indicates the daily dry release, and • indicates the cumulative release.
• Figure 16 is a line graph showing the daily and cumulative release rates of the rotico pint microspheres prepared in Example 24 (actually containing 7.8%) in a simulated release solution of pH 7.4.
• the mouth indicates the daily release
• the reference indicates the cumulative release.
• Fig. 17 is a line graph showing the change in the concentration of rotibutine in the blood of the roticobutan microspheres obtained in Example 24 in the beak (Beagle).
• Figure 18 is a graph showing the daily and cumulative dry release rate in a simulated release solution of pH 7.4, of the roticotine microspheres obtained in Example 25 (26.5%).
• ⁇ indicates the amount of release per
• • indicates the cumulative release amount.
• Figure 19 is a line graph showing the daily and cumulative release rates of the rotibutine microspheres obtained in Example 26 (actually containing 34%) in a simulated release solution of pH 7.4.
• the mouth indicates the daily release amount
• ⁇ indicates the cumulative dry release amount.
• Fig. 20 is a line graph showing the change in the concentration of rotibutine in the blood of the rotibutine microspheres (Beagle) obtained in Example 26.
• Figure 21 is a line graph showing the daily and cumulative release rates of the rotibutine microspheres obtained in Example 27 (actually containing 41%) in a simulated release solution of pH 7.4.
• the mouth indicates the amount of dry volume per unit, and • indicates the cumulative amount of release.
• Figure 22 is a line graph showing the daily and cumulative release rates of the rotibutine microspheres obtained in Example 28 (actually containing 43%) in a simulated release solution of pH 7.4.
• the mouth shows daily # ⁇ , and the climb indicates the cumulative release.
• Figure 23 is a line graph showing the daily and cumulative release rates of the roticotine microspheres obtained in Example 29 (actually containing 47%) in a simulated release solution of pH 7.4.
• the mouth shows the daily dry dose, and the climb indicates the cumulative release.
• the long-acting sustained-release preparation for treating Parkinson's disease of the present invention comprises an effective dose of a dopamine receptor agonist drug and an appropriate amount of a biodegradable medicinal polymer adjuvant, such as an injection slow microsphere, an injection gel or Implants, etc.
• the slow-drying preparation of the present invention may further comprise other preparations or components necessary for administration, such as a solvent, a buffer, an isotonic agent, in addition to the above-mentioned main components, that is, a dopamine receptor agonist pharmaceutical ingredient and a medicinal polymeric adjuvant. And so on, there is no limitation in the present invention.
• a solvent such as a solvent, a buffer, an isotonic agent, in addition to the above-mentioned main components, that is, a dopamine receptor agonist pharmaceutical ingredient and a medicinal polymeric adjuvant.
• the dopamine receptor agonist drugs are roticotine, pramipexole, ropinirole, pergolide, cabergoline, terguride, quetiapine, sumanirole, SLV-30, adrogol ide (ABT) - 431 ), Dinapsol ine and Ying - 1110 and One of them, a combination of two or more of their derivatives, or a pharmaceutically acceptable salt.
• the above pharmaceutically acceptable salt is a salt of a dopamine receptor inhibitor drug and a pharmaceutically acceptable acid.
• it may be a pharmaceutically acceptable salt with an inorganic acid, an organic acid or an acidic amino acid.
• the inorganic salt is preferably hydrochloric acid, sulfuric acid, phosphoric acid or nitric acid;
• the organic acid is selected from the group consisting of citric acid, fumaric acid, maleic acid, acetic acid, benzoic acid, sulfonic acid, naphthalenesulfonic acid or p-toluenesulfonic acid;
• the amino acid is preferably glutamic acid or aspartic acid or the like.
• the pramipexole and its derivatives or pharmaceutically acceptable salts in the present invention may be selected from the related compounds disclosed in EP 186 087 and US Pat. No. 4,868,812, and other improved compounds disclosed in the literature or pharmaceutically acceptable salts thereof, preferably the free base of pramipexole. Or JL dihydrochloride.
• Ropinirole and its derivatives or pharmaceutically acceptable salts are selected from the related compounds disclosed in US Pat. No. 4,452,808, and may also be selected from the derivatives of ropinirole disclosed in other literatures or pharmaceutically acceptable salts thereof, preferably ropinirole. Free base or ropinirole hydrochloride.
• Pergolide and its derivatives or pharmaceutically acceptable salts are related compounds disclosed in US Pat. No. 4,166, 821, and may also be selected from the perindopamine of the pergolide or a pharmaceutically acceptable salt thereof disclosed in other literatures, preferably free of pergolide. Alkali or pegolide of methanesulfonate.
• Cabergoline and its derivatives or pharmaceutically acceptable salts are related compounds disclosed in US Pat. No. 4,528,892 and ⁇ 888,243, and may also be selected from derivatives of ergoline disclosed in other literature or pharmaceutically acceptable salts thereof, preferably free of cabergoline. Alkali or cabergoline diphosphate.
• Terguride and its derivatives or pharmaceutically acceptable salts are related compounds as disclosed in US Pat. No. 3,953,454 and DE 300,175, and may also be selected from derivatives of the special ergots or pharmaceutically acceptable salts thereof, preferably terguride. Free base or ergotamine maleate.
• quetiapine and its derivative or a pharmaceutically acceptable salt thereof are related compounds disclosed in US Pat. No. 4,558,818, EP77754, and may also be selected from all-high-lit derivatives disclosed in other literatures or pharmaceutically acceptable salts thereof, preferably quetiapine Free base or quetiapine hydrochloride.
• Sumanirole and its derivatives or pharmaceutically acceptable salts are selected from the related compounds disclosed in US Pat. No. 5,478, 734, and may also be selected from the Sumanirole derivatives disclosed in other literatures or pharmaceutically acceptable salts thereof, preferably the free base of sumanirole or sumaniro le maleate.
• SLV-308 and derivatives or pharmaceutically acceptable salts thereof are selected from the related compounds disclosed in WO 00/29397, and may also be selected from derivatives of SLV-308 disclosed in other literature or pharmaceutically acceptable salts thereof, preferably the free base of SLV-308. Or its hydrochloride, and the like.
• Adrogolide (ABT-431) and its derivatives or pharmaceutically acceptable salts are selected from the related compounds disclosed in the 422,858 patent, and may also be selected from derivatives of adroglide disclosed in other literature or pharmaceutically acceptable salts thereof, preferably the free base of adrogolide. , adrogolide hydrochloride or transformant A-86929 for adrogolide, and the like.
• Dinapsoline and its derivatives or pharmaceutically acceptable salts are selected from the related compounds disclosed in the Patent No. 7/06799, and may also be selected from other disclosed derivatives of Dinapsoline or a pharmaceutically acceptable salt thereof, preferably dinapsoline free base or dinapsoline. Argonate or the like.
• BAM-1110 and its derivatives or pharmaceutically acceptable salts may also be selected from derivatives of BAM-1110 or pharmaceutically acceptable salts thereof disclosed in other literature, preferably BAM-1110 free base or BAM - 1110 maleate and so on.
• the long-acting sustained-release preparation of the dopamine receptor agonist of the present invention is most preferably a roticotine-based drug, that is, a roticotine compound and a derivative thereof or a pharmaceutically acceptable salt thereof, as the active ingredient to be used.
• a hydrogen atom, d- is represented.
• R 2 represents a hydrogen atom, 0 1 - € 1 .
• An alkyl group (preferably ( 1 - 0 5 ), X represents a carbon atom or a nitrogen atom or an oxygen atom or a sulfur atom; n is any integer of 1 - 10, preferably n is any integer of 1 - 3, and n is optimal 2;
• the pharmaceutically acceptable salt thereof is a salt of rotibutine and hydrochloric acid, acetate, phosphoric acid, sulfuric acid, lactic acid or citric acid;
• the above roticotine And derivatives thereof are preferably roticotine, roticotine ethyl ester, roticobutyl propyl ester and roticotine benzyl ester, and roticotine butyl acrylate and rotico butyl isophthalide or they
• the hydrochloride salt is as shown in the following table (1), (11), (III) or (rv):
• the compounds (II) ⁇ (VI) are, in order, roticotine ethyl ester, roticopropionate, roticot butyl benzoate, ro Tetrabutyl butyrate and rotibutine isobutyl ester.
• roticotine is most preferred, that is, the compound (1), and the pharmaceutically acceptable salt thereof is preferably JL acid roticobutane.
• the active ingredient in the long-acting sustained-release preparation of the present invention may be not only the above-mentioned drug, but also a metabolite or a transformant (e.g., a prodrug, etc.) of the above-mentioned drug having activity.
• the biodegradable medicinal polymer auxiliary material in the invention is selected from the group consisting of polylactide, glycolide, polylactic acid, polyglycolic acid, poly-3-hydroxybutyrate, poly(3 ⁇ 4 ester), polyanhydride, polyhydroxybutyrate a hydroxyl group; an acid copolymer, a polypropylene dextran, a poly L acid-polyethylene glycol, a polyglycolic acid-polyethylene glycol, or a mixture of two or more thereof, the molecular weight of which is Between 2,000 and 1, 000,000 Daltons; the medicinal polymer adjuvant of the present invention is preferably polylactide-glycolide, polylactic acid, polyhexyl ester, polyanhydride, polyhydroxybutyrate One of hydroxyvalerate copolymers or a combination of two or more of them.
• the medicinal polymer auxiliary material of the invention when the sustained release preparation is a microsphere for injection, further Preferred is polylactide-glycolide, which may have a molecular weight in the range of from 2,000 to 100,000 Daltons, more preferably from 5,000 to 50,000 Daltons.
• the polymerization ratio of lactide to glycolide is between 95:5 and 5:95, preferably 75:25 to 25:75, and most preferably about 50:50.
• the drug-month polymer adjuvant of the present invention when the sustained-release preparation is an injection gel or an implant, is preferably a polylactic acid or a polyanhydride having a molecular weight ranging from 2,000 to 1, 000,000 Daltons.
• the weight percentage of the dopamine receptor agonist drug in the sustained release preparation should be 5 - 50%, preferably 10 - 50%, more preferably 10 - 40%, and most preferably 10 30%; pharmaceutically acceptable polymeric adjuvant content of from 50 to 95% by weight, preferably from 50 to 90% by weight, further preferably from 60 to 90% by weight, most preferably from 70 to 90%.
• the content of the dopamine receptor agonist is less than 5% by weight, a sufficiently high blood concentration cannot be ensured; conversely, if it is higher than 50% by weight, there is a possibility that the drug cannot be smoothly dried and may cause side effects.
• the dopamine receptor agonist drugs are in a certain content range in the sustained-release preparation, these drugs are uniformly distributed in the medicinal polymer adjuvant, and are in a solid solution state, which can effectively ensure the smooth release of the drug, and vice versa. If the content is too high, the drug is not present in the preparation in the form of a solid solution, and there is a possibility that the release of the drug is uneven. This is especially important for sustained release microspheres. The drug is not present in the spheroid in the form of a solid solution and is considered to be an important cause of drug burst release caused by microspheres. For other sustained-release preparations of the present invention such as gels for injection or implants, since the blood does not flow like the microspheres, the possibility of burst release is small, so the content restriction can be appropriately relaxed, but It is also suitable for no more than 50%.
• the roticotine microspheres are taken as an example for illustration.
• a comparison of the lid thermal analysis spectra of rotibutine-dried microspheres and rotibutine itself prepared by various methods at various levels is shown in FIG.
• the curve a is the difference heat curve of the original drug when the rotibutine loading amount is 30% or less
• the curve b is the curve when the drug loading amount is 34%
• the curve c is the drug loading.
• curve d is the differential thermal curve of the original rotibutine. It can be seen from Fig. 1 that roticotine is a crystalline solid with a melting point of 79 to 80 ° C (curve d ).
• the roticotine When the microspheres are loaded within 30%, the roticotine has good compatibility with the copolymer of lactic acid and glycolic acid, and the roticotine is substantially completely dissolved in the polymer carrier to form a solid solution.
• the melting point without roticotine can be measured (curve a). However, when the drug loading increased to 34%, the melting point of roticodine was 73. C begins to appear (curve b) and rises as the drug loading increases. For example, when the drug loading is 47%, the melting point of roticotine rises to 76 °C (curve c), and the heat absorption area also increases.
• the melting point and endothermic area of roticotine in the microspheres are lower or lower than the melting point of pure roticotine and the endothermic area (curve d), which is due to The roticotine crystals in the microspheres are imperfect, while the JL is only partially caused by the crystallization of rotibutine.
• the above-mentioned single-component pharmaceutical compound can be prepared into a sustained-release preparation, but also different pharmaceutical ingredients in the above-mentioned medicine can be combined, and then the medicinal polymer auxiliary material can be made into two or more kinds.
• Long-acting sustained-release preparations with the same or different sustained-release effects of the drug ingredients such as long-acting sustained release ball for injection, gel for injection or implant, to achieve synergistic effects of a variety of different drugs.
• sustained release microspheres for injection, the implant or the gel for injection of the long-acting sustained-release preparation of the present invention may be administered at least once a week, preferably at least once every two weeks, wherein the implant and the gel are preferably Dosing once every at least one month.
• microspheres for injection, the implant, and the gel for injection of the present invention are separately described below.
• the present invention discloses a sustained release microsphere of a dopamine receptor agonist drug (also referred to in the present invention)
• the preparation method for microspheres for injection, microspheres can be prepared by a conventional preparation method in the art.
• the particle size of the slow-drying microspheres for injection of the dopamine receptor agonist of the present invention is preferably between 1 and 250 ⁇ m, preferably between 50 and 200 ⁇ m. This can maintain a certain time, biodegradability and does not affect blood circulation after injection into the body, because the particle size is too small, it is difficult to maintain long-term efficacy, and at the same time may block capillaries, affecting microcirculation; The initial release is too slow to reach the therapeutically effective blood drug concentration.
• the drug-loading amount of the active ingredient should not exceed ⁇ , otherwise, when the patient is administered, the amount of the injected microspheres is too large, causing unnecessary side effects such as pain and the like; When the amount is too large, when the patient is administered, the drug has a serious burst release, which is likely to cause an overdose.
• the content of the pharmaceutical ingredient is 5 - 50% by weight
• the amount of £ is selected to be 10 - 40% by weight, most preferably 10 - 30%
• the amount of the pharmaceutically degradable polymeric auxiliary material may be 50 - 95 weight % / » It is preferably from 60 to 90% by weight, most preferably from 70 to 90% by weight.
• the dopamine receptor agonist drug content is less than 5 parts by weight. /.
• a sufficiently high blood concentration cannot be guaranteed; on the other hand, if it is higher than 50% by weight, the drug cannot be smoothly released, and a sudden release may occur, which may cause a side effect.
• a suitable amount of gas should be no more than 50%, and most preferably within 30%.
• the most preferred drug loading is 10°/. Up to 30%.
• the dopamine receptor agonist drug is preferably roticotine and a derivative or a pharmaceutically acceptable salt thereof, wherein roticotin and its ruthenium organism are preferably rotibutine , roticotine ethyl ester, roticobutyl propyl ester, roticoyl T butyl ester, roticotine isobutyl ester and roticotine benzyl ester, the pharmaceutically acceptable salt thereof is preferably hydrochloric acid.
• roticotine and its derivatives or pharmaceutically acceptable salts constitute rotibutine and medicinal polymeric excipients.
• the total weight is from 5 to 50%, preferably from 10 to 50%, more preferably from 10 to 40%, most preferably from 10 to 30%; and the pharmaceutically acceptable polymer adjuvant content ratio is from 50 to 95% by weight. /. It is preferably from 50 to 90% by weight, further preferably from 60 to 90% by weight, most preferably from 70 to 90%.
• the roticotine and its derivatives or pharmaceutically acceptable salts should be in a solid solution, that is, the active ingredient and the auxiliary materials are not phase separated, to be homogeneous. The form exists.
• microspheres of the present invention can be obtained by conventional preparation methods of microspheres in the art, such as spray drying, solvent evaporation, and spray extraction, but are not limited to the methods exemplified in the present invention.
• a dopamine receptor agonist drug and a biodegradable pharmaceutical excipient are first dissolved in an organic solvent to prepare a courtesy phase.
• a continuous aqueous phase is prepared by using a water-soluble pharmaceutically acceptable polymer compound, and the organic phase is injected into the continuous phase through a thin tube, and fully emulsified to form microspheres under vigorous stirring such as mechanical stirring or ultrasonication, and then evaporated to dry organic Solvent, the microspheres formed by filtration are separated and dried. If necessary, the microspheres may be subjected to water washing, grading, etc., in a conventional manner, and subjected to drying under reduced pressure drying or lyophilization, followed by dispensing.
• the organic solvent should be a low-boiling organic solvent having a sufficiently volatile and low residual from the viewpoint of operation, specifically, for example, dichloromethane, chloroform, ethyl acetate, acetic acid, a mixed solvent composed of them, and the like.
• the medicinal polymer for preparing the continuous aqueous phase may be one, two or more combinations of polyvinyl alcohol, sodium carboxymethyl cellulose, polyvinyl pyrrolidone, sodium polymethyl propyl acrylate and sodium polyacrylate. But it is not limited to this.
• the content of the dopamine receptor agonist drug and the degradable medicinal adjuvant in the organic solvent is not limited as long as the organic solvent can be dissolved, but the balance between the feasible concentration and the viscosity and the use of the organic solvent are less.
• the concentration of yoghurt is l - 30% (w/v).
• polyvinyl alcohol, sodium carboxymethyl cellulose, polyethylidene pyrrole When one or two or more of the alkyl ketone, sodium polymethacrylate and sodium polyacrylate are combined to prepare a continuous aqueous phase, the concentration thereof is not particularly limited, but according to its solubility in water, the content in the aqueous phase 01 ⁇ 12.
• the volume ratio of the organic phase to the aqueous phase should be sufficient to sufficiently disperse the organic phase in the aqueous phase to form microspheres of sufficiently fine particle size and uniformity, but if The water phase is too much, the post-treatment is complicated, and the cost is increased. From the above point of view, the volume ratio of the organic phase to the aqueous phase is approximately 1:4 to 1:100.
• Microspheres can also be prepared by spray drying.
• spray-drying method is used to prepare the sustained-release microspheres of the dopamine receptor agonist drug, the dopamine receptor agonist drug and the biodegradable medicinal adjuvant are fully dissolved in an organic solvent to prepare an organic solution;
• Microspheres are prepared by conventional spray drying. If necessary, the microspheres may be subjected to water washing, grading, etc., according to a conventional method, and then dispensed.
• the organic solvent may be, but not limited to, dichloromethane, chloroform, ethyl acetate, dioxane, diethyl ether, acetone, tetrahydrofuran, glacial acetic acid, and a mixed solvent thereof.
• the content of the medicinal adjuvant in the organic solvent is not limited as long as the organic solvent can dissolve the auxiliary material, but from the viewpoint of the balance of the feasible concentration and the saving of the organic solvent, the preferred concentration is 1 - 30% ( w/v ).
• Microspheres can also be prepared by spray extraction.
• spray-extraction is used to prepare dopamine receptor agonist microspheres, it is an organic solvent (which can dissolve dopamine receptor agonists and biodegradable drugs).
• An organic solvent for molecular adjuvants The dopamine receptor agonist drug and the biodegradable medicinal polymer adjuvant are fully dissolved and formulated into an organic solution, which is sprayed to an organic non-solvent (dopamine receptor agonist drug and bioreagent).
• the degraded medicinal polymer excipient in the organic solvent in which it is dissolved or water is extracted to form a microsphere, and if necessary, the microsphere may be washed, graded, etc. according to a conventional method, and then divided. Installed.
• the organic solvent may be dichloromethane, chloroform, ethyl acetate, dioxane, diethyl ether, acetone, tetrahydrofuran, benzene, toluene, glacial acetic acid, and a mixed solvent thereof, but Not limited to this.
• the organic non-solvent may be, but is not limited to, decyl alcohol, ethanol, propanol, isopropanol, petroleum ether, alkane, paraffin oil, and the like, and a mixed non-solvent composed of them.
• the content of the medicinal adjuvant in the organic solvent is not limited as long as the organic solvent can dissolve the adjuvant, but from the viewpoint of the balance of the feasible concentration and the saving of the organic solvent, the concentration is preferably 1 - 30% ( w/v ).
• the spray drying method is preferred from the preparation of the microsphere solvent evaporation method and the spray drying method from the uniformity of the particle diameter of the produced microspheres and the ease of handling.
• the solvent evaporation method is preferred from the viewpoint of lowering the initial front discharge.
• the microspheres After the preparation of the dopamine receptor agonist drug microspheres according to the present invention, after the particle size fractionation or if the particle diameter is sufficiently uniform, the microspheres may not be classified, and after being washed and dried, they may be dispensed according to a prescribed dose, and the powder injection may be prepared. When used, it is formulated as an injection in the field (in si tu).
• the powder injection may be directly prepared from the above microspheres, and the suspension is mixed with physiological saline for injection before use to prepare an injection solution.
• a predetermined amount of an isotonic salt, mannitol, glucose, or the like may be mixed in the ball, and a predetermined amount of pure water for injection may be added thereto before use to prepare an injection.
• the microspheres may be suspended and lyophilized according to the amount of injection, and reconstituted before use.
• the method for treating a disease associated with a dopa receptor according to the present invention and a method for treating Parkinson's disease are carried out by administering the above-described injection of a dopamine receptor agonist of the present invention to a patient in need of the above treatment.
• the administration method can be used as long as it can be used as an injection.
• intramuscular injection, subcutaneous injection, intradermal injection, intra-abdominal injection, and the like From the viewpoint of convenience of administration, intramuscular administration and subcutaneous injection are preferred.
• the dosage of the dopamine receptor agonist slow-drying microspheres according to the present invention is, for example, roticortin.
• the dose of roticotine is 10 - each injection. 400mg, injection volume is 1 - 5ml, the preferred injection volume is: 1 - 3ml 0 is injected at least once a week or two weeks. Specifically, it can be appropriately changed according to the actual situation of the patient's age, weight, and disease state.
• the sustained-release microspheres using the dopamine receptor agonist of the present invention can achieve an interval of not less than one week, preferably not less than two weeks, more preferably not less than 20 days, or even more than two months. Interval administration improves the quality of life in patients with Parkinson's disease and avoids the drawback of daily dosing.
• the long-acting sustained-release microsphere prepared by the invention has the advantages of high encapsulation rate, sustained and stable drug release, stable and stable blood concentration in the patient, and has the characteristics of good treatment and low side effects, and truly solves the conventional preparation belt.
• the disadvantage is that it has a good therapeutic effect on patients with Jinsen disease.
• the drug used in the implant of the present invention, and the medicinal polymer excipients and the like are required to be substantially similar to the above-mentioned sustained-release microspheres, and therefore only the differences will be described.
• the content of the pharmaceutical ingredient can be relatively high according to the process under the premise of ensuring moderate release, but it is preferably not more than 50%.
• the implant in the present invention can be prepared by a conventional preparation process in the art, and is preferably prepared by the following methods: Doping a dopamine receptor agonist drug in an organic solvent, and a sufficiently difficult medicinal polymer adjuvant Mix well, then rn hot extrusion to prepare a stick-shaped implant, the organic solvent is methanol, ethanol, isopropanol, ethylene, butyl ether, methyl ethyl ether, methyl butyl ether, hexane, heptane, octane or A mixture of them, but is not limited to this.
• the implant of the present invention can be implanted subcutaneously by conventional surgery or injection, the drug slowly diffuses from the implant into the blood, and enters the circulatory system, and the implant of the present invention can be administered to the patient at least every month. Once, it can even be administered once every 4-6 months, which greatly facilitates the use of Parkinson's patients.
• the injection gel is injected into the body to form a local implant, according to the process, as long as it is soluble in the organic solvent, the content of the pharmaceutical component can be relatively high under the premise of ensuring moderate release, but It is better to not exceed 50%.
• the gel for injection of the present invention can be prepared by a conventional preparation technique in the art, and is preferably prepared by the following method: Weighing an appropriate amount of dopamine receptor agonist drugs, degradable medicinal polymer adjuvants, and dissolving in an organic solvent The resulting gel for injection was prepared.
• the solvent is N-methylpyrrolidone, a pharmaceutically acceptable organic solvent such as DMS0, but is not limited thereto.
• the injection gel of the present invention can be directly injected into the skin or muscle, the organic solvent rapidly diffuses into the body fluid and is metabolized, and the gel solidifies under the skin or muscle to form an implant, and the drug gradually diffuses from the implant to the body. Circulatory system.
• the gel for injection of the invention can be administered to a patient once for more than two weeks, and is convenient to use, and overcomes the technical defects existing in the conventional oral administration.
• the long-acting sustained release preparation of the dopamine receptor agonist drug of the present invention will be further illustrated by the following examples and experimental examples without any limitation on the present invention.
• the particle diameter of the microspheres in the following examples was measured using a L2000 type fully automatic laser particle size analyzer (Beckman Coul ter) which is familiar to those skilled in the art.
• the concentration is determined by high performance liquid chromatography (HPLC) according to literature methods, for example, as in the Journal of Modern Applied Pharmacy, 1993, 10 (1), 51-52; Chinese Journal of Pharmaceutical Industry, 1999, 30 (8), 363 - 365, etc. are disclosed.
• Fig. 3 is a scanning electron micrograph of the sustained release microsphere obtained in Example 1.
• polylactide-glycolide (lactide: glycolide-50: 50, molecular weight 25000) 0. 85g, prepared according to the method of Example 1 to obtain medicine 15 ° / . , with a micro-rate of 1 - 250m, sifting, and holding microspheres with a particle size larger than 150 microns.
• microspheres containing 15% of the drug and having a particle diameter of 1 to 250 m were prepared by dispersing in 5 ml of dichloromethane, and sieved to remove microspheres having a particle diameter of more than 150 ⁇ m.
• the release test was carried out by simulating in vivo conditions. According to the study by the present inventors, a buffer solution having a certain pH (pH 7.4) is used. (Sodium phosphate buffer solution), the drug release behavior is similar to that in the body, so although its environment is not exactly the same as the human body environment, it is generally considered to be able to express the release form in the body (see Experimental Example 3 and Figure 13).
• Sampling method Centrifuge the tube at 3600 rpm for 20 min, accurately absorb 3 ml of solution, and add 3 ml of release medium to the tube, and take out the solution with IIPLC.
• Example 1 100 Day 0 5. 8 1. 6 1. 2 2. 0 3. 2 3. 7 3. 4 3. 8 Accumulation 0 5. 8 7. 4 9. 8 13. 8 20. 2 27. 6 34. 5 42. 1
• Example 2 100 Day 0 11. 5 11. 2 6. 1 6. 5 5. 7 5. 1 4. 7 3. 5 Accumulation 0 11. 5 22. 7 35. 0 48. 1 59. 5 69. 7 79. 1 86. 1
• Example 3 200 Day 0 3. 7 5. 7 11. 4 11. 1 7. 3 5. 1 4. 3 J 3. 0 Accumulation 0 3. 7 9. 4 32. 2 54. 4 69. 0 79. 2 88. 0 94. 0
• Example 4 200 Day 0 13. 1 1. 5 6. 1 5. 6 3. 9 3. 5 3. 4 2. 6 Accumulation 0 13. 1 14.
• microspheres obtained in Examples 11 and 13 were subjected to the same measurement in the same manner as in Experimental Example 1, except that the sampling time points (days) were 0, 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36 and 38 days.
• the in vitro release efficacies of the microspheres of Examples 11 and 13 under the conditions of pH 7.4 are shown in Figures 10 and 11, respectively. It can be seen from the figure that the stable release time of the sustained release spheroid of the rotibutine of the present invention can even be More than 30 days.
• Experimental Example 3 In vivo release experiment of sustained release microspheres
• Pretreatment of plasma samples Take 500 ⁇ of the plasma sample and place it in a stoppered tube. Add the internal standard solution (1 ng/mL diphenhydramine-water (50:50, v/v) solution) 100 ⁇ , add 100 ⁇ M methanol-water (50: 50, v/v) and 100 ⁇ 1 Na 2 C0 3 solution, mix; add 3 mL of n-hexane-dichloromethane-isopropanol (300: 150: 15, v/v /v), vortex mixing for 1 min, reciprocating for 15 min (240 times/min), centrifugation for 5 min (3500 rpm), taking the upper organic phase in another tube, 25. C. The nitrogen stream was blown dry, the residue was added to 100 ⁇ of the mobile phase to dissolve, vortex mixed, and 20 was subjected to LC/MS/MS analysis.
• Chromatographic conditions Zorbax Extend- C 18 column, 5 ⁇ vertical diameter, 150 X 4.6 ram ID, Agilent, USA; Mobile phase: acetonitrile-water-formic acid (300: 300: 6, v/v/v); Flow rate: 0.7 mL/min; column temperature: 37. C; Injection volume: 20 ⁇ .
• Conditional ion source ion spray ionization source; ion spray voltage: 5000 V; temperature: 450. C; source gas 1 (GS1, N 2 ) pressure: 50 psi; gas break 2 (GS2, N 2 ) pressure: 50 psi; air curtain gas (N 2 ) pressure: 15 psi; positive ion mode detection; scanning mode is multiple Reaction monitoring (MRM); DP voltage: 56 V; 5 and collision gas (N 2 ) pressure: 3 psi; ionization reactions for quantitative analysis are » ⁇ 317.1 »/ ⁇ 147 ⁇ 1 (MD102) and ⁇ ? ⁇ 256.1 ⁇ m/z 167.1 (Diphenhydramine).
• the working curve was prepared by taking 0.5 mL of blank plasma and adding MD102 standard series solution ⁇ to prepare plasma samples corresponding to plasma concentrations of 0.01, 0.03, 0.10, 0.30, 1.00 and 2.00 ng/mL according to the Pharmacopoeia of the People's Republic of China 2000 Edition Two
• the equation is the standard curve.
• Fig. 12 is a graph showing the change in concentration of rotibutine in the blood of the slow-drying microspheres obtained in Example 3 in vivo (Beagle dogs).
• Figure 13 is a line graph of the daily or cumulative release rate of the slow-drying microspheres obtained in Example 3 in the simulated release solution of H7.4.
• the in vivo experiment (Beagle dog) shows the change in the concentration of roticobutine in the blood. Comparison.
• the sustained release microsphere of the present invention can achieve a smooth release in at least two weeks.
• Experimental Example 4 Implant release test in vitro
• the sustained release microspheres were tested in vivo against the dog.
• the dose of roquebutine is 2.75mg/kg (calculated according to the weight of the Beagle dog of 10 kilograms, which is equivalent to one weight of 65 kilograms of adult injection of 1150 grams of drug containing 7.8% of microspheres).
• the sputum is suspended in the physiological saline for injection, intramuscularly administered, within 1 to 30 days, ⁇ k, HPLC-MS detection, blood concentration is 0.05 - 0.4 ng / ml.
• the sustained release microspheres can achieve a smooth release at least 30 days, but the blood concentration of the drug is relatively low, which is difficult to meet the blood concentration requirement (>0.5 ng/L) for treating patients with Parkinson's disease, especially in the developmental period.
• the amount administered will cause discomfort and suffering to the patient due to excessive injection volume.
• Figure 17 is a line diagram showing the change in the concentration of rotibutine in the blood of the rotibutine microspheres (actually containing 3 ⁇ 4 is 7.8%) obtained in Example 24.
• Example 25
• the sustained release microspheres were tested in vivo against the dog.
• the dose of roticotine is 5. 5mg/kg (according to the weight of the Beagle dog, 10 kg, after conversion, equivalent to a weight of 65 kg, an injection of 520 grams of a drug containing 34. /. ⁇ microspheres), : ball mixing Suspended in saline for injection, intramuscular injection, from 1 to 11 days! 3 ⁇ 4 , blood was taken, HPLC-MS detection, blood concentration was 28 ⁇ 0. 05 ng / ml.
• Fig. 20 is a line graph showing the change in the concentration of roticon in the blood of the rotibutine microspheres (the actual drug content is 34%) obtained in Example 26.
• the invention adopts a biodegradable polymer-embedded dopa face receptor agonist drug to prepare a long-acting sustained-release emperor agent, such as an injection microsphere, an injection gel face, an implant, which can reach more than two weeks. Dosing once, especially if the implant can be administered more than once for one month, greatly facilitates the administration of patients with Parkinson's disease and other diseases associated with dopamine receptors.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Dermatology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Inorganic Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurology (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Psychology (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=36089849

Family Applications (1)

Country Status (9)

Cited By (11)

Families Citing this family (12)

Citations (2)

Family Cites Families (17)

• 2005
  • 2005-09-21 PL PL05792179T patent/PL1797871T3/pl unknown
  • 2005-09-21 EP EP05792179.3A patent/EP1797871B1/en not_active Expired - Lifetime
  • 2005-09-21 AU AU2005287743A patent/AU2005287743B2/en not_active Ceased
  • 2005-09-21 WO PCT/CN2005/001521 patent/WO2006032202A1/zh not_active Ceased
  • 2005-09-21 KR KR1020077008896A patent/KR20070059161A/ko not_active Ceased
  • 2005-09-21 US US11/663,411 patent/US8691277B2/en active Active
  • 2005-09-21 CA CA2581143A patent/CA2581143C/en not_active Expired - Fee Related
  • 2005-09-21 ES ES05792179.3T patent/ES2536460T3/es not_active Expired - Lifetime
  • 2005-09-21 JP JP2007532749A patent/JP5081622B2/ja not_active Expired - Lifetime
• 2014
  • 2014-03-17 US US14/182,652 patent/US9220782B2/en not_active Expired - Lifetime

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events